Browse drugs

…D) SCS intake duration was 23.5 (21.3) and 34.9 (26.4) days for dupilumab and placebo, respectively; antibiotic intake duration was 17.8 …

…s achieved clinical or histological remission prior to starting dupilumab. Following dupilumab therapy, two patients (50%) demonstrated b…

…dupilumab n=573; placebo n=562) had baseline BEC ≥300 cells/µL. Dupilumab reduced annualized exacerbation rates vs placebo by 36.9% (BEC …

…topical corticosteroids, and more recently, to biologic agents. Budesonide remains a widely adopted corticosteroid treatment, while dupilu…

…. An exception to this timeline is initiation of treatment with dupilumab, whereby repeat endoscopy is performed after six months of trea…

…l interaction P values for data presented were >0.05.Conclusion Dupilumab reduced moderate or severe exacerbation rates, and improved lun…

…erbation rates were observed regardless of baseline IgE levels (dupilumab: 0.56 [95% CI:0.50–0.63] for 100 IU/mL to 0.53 [0.44–0.63] for …

…to pruritus and sleep outcomes compared with those treated with tralokinumab.Conflict of Interest No conflict of interest…

…Conclusions In patients with type 2, moderate-to-severe asthma, dupilumab significantly increased spirometry-derived ratios, indicating i…

…umab (28.6%) and dupilumab (14.3%), there were no patients with omalizumab.Conclusion and Relevance 70.8% of corticosteroid dependent pati…

… Evaluating Respiratory Symptoms in COPD (E-RS:COPD).Results In dupilumab recipients, moderate or severe exacerbations were reduced by 22…

…enrol 50 paediatric patients aged 2–18 years with AD undergoing dupilumab treatment. The participants will receive intranasal LAIV, follo…